76532-33-7

Basic information

• Product Name: methyl-(naphthalen-2-ylmethyl)azanium
• Synonyms: methyl-(naphthalen-2-ylmethyl)azanium;Methyl-2-naphthaleneMethylaMine;N-Methyl-1-(naphthalen-2-yl)MethanaMine;N-Methyl(naphthalen-2-yl)MethanaMine;Terbinafine Related Compound 2;N-methyl-1-(naphthalen-2-yl);N-Methylnaphthalene-2-methanamine
• CAS NO: 76532-33-7
• Molecular Formula: C₁₂H₁₃N
• Molecular Weight: 171.24
• Product Categories: Amines;Aromatics
• Mol File: 76532-33-7.mol
• Article Data: 10

Chemical Properties

• Melting Point: 232-233 °C
• Boiling Point: 287.9°C at 760 mmHg
• Flash Point: 146.7°C
• Appearance: /
• Density: 1.036g/cm³
• Vapor Pressure: 0.00242mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.50±0.10(Predicted)
• CAS DataBase Reference: methyl-(naphthalen-2-ylmethyl)azanium(CAS DataBase Reference)
• NIST Chemistry Reference: methyl-(naphthalen-2-ylmethyl)azanium(76532-33-7)
• EPA Substance Registry System: methyl-(naphthalen-2-ylmethyl)azanium(76532-33-7)

Safety Data

• Hazardous Substances Data: 76532-33-7(Hazardous Substances Data)

Usage

Description

Methyl-(naphthalen-2-ylmethyl)azanium is an organic compound with the chemical formula C11H13N. It is a quaternary ammonium salt derived from naphthalene, a polycyclic aromatic hydrocarbon. methyl-(naphthalen-2-ylmethyl)azanium has a methyl group attached to a naphthalene ring, which is connected to a quaternary nitrogen atom.

Uses

Used in Agricultural Industry:
Methyl-(naphthalen-2-ylmethyl)azanium is used as an intermediate in the preparation of detoxification inhibitors of the crucifer phytoalexin Brassinin. It serves as a potential fungicide against Leptosphaeria maculans, a plant pathogen that causes blackleg and stem canker diseases in cruciferous crops. By inhibiting the detoxification process of Brassinin, this compound helps to enhance the effectiveness of fungicides and protect crops from diseases.

InChI:InChI=1/C12H13N/c1-13-9-10-6-7-11-4-2-3-5-12(11)8-10/h2-8,13H,9H2,1H3

Upstream product

• 120350-92-7 methyl-[2]naphthylmethylen-amine 
• 66-99-9 β-naphthaldehyde 
• 74-89-5 methylamine 
• 3815-22-3 N-methyl-2-naphthalenecarboxamide 
• 125660-64-2 N-methyl-1-(naphthalene-2-yl)methanimine 
• 2506-41-4 1-chloromethylnaphthalene 
• 5470-96-2 quinoline 2-carbaldehyde 
• 939-26-4 2-bromomethylnaphthyl bromide 

Downstream Products

• 1443159-49-6 5-(biphenyl-4-ylmethyl)-N-methyl-N-(naphthalen-2-ylmethyl)-1H-tetrazole-1-carboxamide 
• 1443159-53-2 5-(biphenyl-4-ylmethyl)-N-methyl-N-(naphthalen-2-ylmethyl)-2H-tetrazole-2-carboxamide 
• 1262999-67-6 2-(methyl(naphthalen-2-ylmethyl)amino)benzaldehyde 
• 104257-88-7 (E)-N-<3-(1-cyclohexenyl)-2-propenyl>-N-methyl-2-naphthalinmethanamin 
• 98977-54-9 (E)-N-methyl-N-(3-phenyl-2-propenyl)-2-naphthalenemethanamine 
• 98978-36-0 3--1-phenyl-1-propanol 
• 98978-29-1 3--1-phenyl-1-propanone 
• 104257-80-9 N-<3-(1-cyclohexenyl)-2-propinyl>-N-methyl-2-naphthalinmethanamin 

Relevant articles and documents

Identification of impurities in the production of terbinafine hydrochloride

The purity of the parent substance of (E)-N-(6,6-dimethylhept-2-en-4-ynyl)- N-methylnaphth-1-ylmethylamine (terbinafine) is evaluated via TLC identification of the main impurities appearing during its synthesis via alkylation of N-methylnaphth-1-ylmethylamine with 1-chloro-6,6-dimethyl-2-hept-2-en-4-yne The possible formation of impurities including N-methyl-N,N-di(methylnaphth-1-yl) amine, N-methylnaphth-1-ylmethylamine, N-methylnaphth-2-ylmethylamine, (E)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-1-ylmethylamine, (Z)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-1-ylmethylamine, (E)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-2-ylmethylamine, and (Z)-N-(6,6-dimethylhept-2-en-4-ynyl)-N-methylnaphth-2-ylmethylamine was confirmed by means of countersynthesis.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound which is a pyrimidine of formula (I): The compounds are inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

FAB I INHIBITORS

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.